Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis DOI
Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Dermatitis, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Abstracts:Background: Some patients with moderate-to-severe atopic dermatitis (AD) show insufficient response to treatment tralokinumab, an anti-interleukin-13 antibody. Identifying predictive factors for poor responders tralokinumab can help optimize strategies AD patients. Objective: To identify defined as investigator's global assessment >2 at week 12 or 24. Methods: A prospective study was conducted from October 2023 August 2024, including 109 Japanese AD. Baseline features were compared between versus Results: Poor showed higher baseline eczema area and severity index (EASI), lactate dehydrogenase (LDH), eosinophil-to-lymphocyte ratio (ELR) responders. 24 had older age, longer disease duration, proportions of previous systemic therapies, dupilumab, 15 mg upadacitinib treatment, Conclusions: Higher EASI, LDH, ELR may predict 12. Older usage therapy, the above well avoid treatment.

Language: Английский

Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis DOI
Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

et al.

Dermatitis, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Abstracts:Background: Some patients with moderate-to-severe atopic dermatitis (AD) show insufficient response to treatment tralokinumab, an anti-interleukin-13 antibody. Identifying predictive factors for poor responders tralokinumab can help optimize strategies AD patients. Objective: To identify defined as investigator's global assessment >2 at week 12 or 24. Methods: A prospective study was conducted from October 2023 August 2024, including 109 Japanese AD. Baseline features were compared between versus Results: Poor showed higher baseline eczema area and severity index (EASI), lactate dehydrogenase (LDH), eosinophil-to-lymphocyte ratio (ELR) responders. 24 had older age, longer disease duration, proportions of previous systemic therapies, dupilumab, 15 mg upadacitinib treatment, Conclusions: Higher EASI, LDH, ELR may predict 12. Older usage therapy, the above well avoid treatment.

Language: Английский

Citations

0